Back

Exrecise capacity dynamics in non-hodgkin lymphoma patients

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 3 Cardiotoxicity of Drugs and Other Therapies HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Daniela Bursacovschi

Institute of Cardiology, Chisinau (Moldova (Republic of))

7 More presentations in this session

Presentation thumbnail
Safety and effect of EMPAGLIFOZIN in patients with HF reduced LVEF in renal function replacement therapy. Adjustments needed for real life
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides Video
Presentation thumbnail
Correlation of sST2 with chosen biochemical parameters and influence on prognosis in patients hospitalized due to HFrEF.
Doctor M. Dudek (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Long-term hydroxychloroquine exposure impairs the left ventricular longitudinal strain
Doctor R. Didier (Dijon, FR)
Abstract Slides Video
Presentation thumbnail
The impact of antitumor therapy on cardiac systolic function in patients with non-hodgkin lymphoma
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Implications of pulmonary artery pressures during both heart failure and non heart failure hospitalizations for subsequent hospitalization events
Doctor M. Costanzo (Naperville, US)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments
thumbnail
Congress Presentation
The impact of antitumor therapy on cardiac systolic function in patients with non-hodgkin lymphoma
thumbnail
Congress Presentation
Multimodal predictive model for 6-month treatment-related cardiotoxicity in non-Hodgkin lymphoma patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources